Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function ...Middle East

STOCKHOLM, Dec. 20, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in...

Hence then, the article about calliditas therapeutics announces full fda approval of tarpeyo the only fda approved treatment for iga nephropathy to significantly reduce the loss of kidney function was published today ( Thursday 21/12/2023 - 12:44 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function )

Also on site :

• Best-Selling Author’s Latest ‘Maasverse’ Novel Ranked No. 2 on Amazon Charts—8 Weeks Before Its Release
• ‘Crash Landing on You’ Star Hyun Bin Returns in ‘Made in Korea 2’—What To Know About the 9-Year Time Jump
• ‘I’m a Hepatologist, and This Is the One Thing I Tell Every Patient With Fatty Liver To Start Eating’